Deep Brain Stimulation for Severe, Treatment-Refractory OCD
Five adequate medication trials and three years out of work later, the real question isn't whether deep brain stimulation works — it's whether pharmacotherapy is actually exhausted enough to justify neurosurgery.
J.B., a 46-year-old man, worked as an auto mechanic for over twenty years before his OCD forced him to stop three years ago; he now lives with his elderly mother, who manages most of the household because his contamination and checking rituals consume most of his day. He has mild hypertension, stable on amlodipine, and no other significant medical history.
His OCD began in his late twenties with mild checking behaviors he mostly worked around, then escalated sharply after a workplace injury eight years ago that he says "made me realize how much could go wrong that I hadn't checked for." He has since completed five separate adequate medication trials — fluoxetine, sertraline, and fluvoxamine each at maximal tolerated doses for at least 12 weeks; clomipramine augmentation of an SSRI; and a risperidone augmentation trial — documented across two prior treatment centers. He has also completed 18 months of ERP with a specialist OCD therapist, with partial but ultimately insufficient benefit. His Y-BOCS today is 34, extreme range, and he has not worked, driven a car, or eaten a meal his mother did not personally prepare and inspect in over a year.
Deep brain stimulation, most commonly targeting the ventral capsule/ventral striatum, has FDA approval for severe, treatment-refractory OCD under a Humanitarian Device Exemption — a real, if narrower, approval pathway than a standard device clearance, reserved for conditions too rare for a full randomized trial program to be practical. The genuine question the group is weighing isn't whether DBS can help someone this severe; case-series evidence in patients matching his trial history shows real, sometimes substantial Y-BOCS reduction. It's whether his documented history of five medication trials and a full ERP course actually meets the field's own working definition of treatment-refractory before neurosurgery becomes the right next conversation to have with him at all.
Is medication truly exhausted
Five adequate trials across three drug classes, including both an antipsychotic and a clomipramine augmentation, plus eighteen months of real ERP with a specialist — that is a genuinely refractory history by any reasonable reading of the field's own criteria, not a reason to look for a sixth medication combination. I think it's appropriate to refer for DBS evaluation now rather than cycling him through further trials that carry a low probability of success given what's already failed.
I want to check one thing before I agree the medication side is fully closed: I don't see aripiprazole trialed as an augmentation agent, only risperidone, and the two don't have identical trial profiles. It's a narrow gap, and I wouldn't hold up a DBS referral to force it, but I'd want it named explicitly in the refractory-criteria documentation rather than silently assumed covered, since some DBS eligibility protocols look for exactly that kind of gap.
From the surgical side, his documented history already clears what most HDE-era case series used as an inclusion bar, and I'd rather start the formal workup — MRI, neuropsychological baseline testing, and psychiatric clearance — in parallel with any final medication-history gap being closed, rather than sequentially. DBS for OCD is real, FDA-recognized, and reversible in a way ablative procedures aren't, but it is still neurosurgery with its own real risks, and nothing about today's conversation should read as a decision already made on his behalf.
Agreed: an aripiprazole augmentation trial added to close the one documented gap in his medication history, run concurrently — not sequentially — with the formal DBS workup (MRI, neuropsychological testing, psychiatric clearance) that the functional neurosurgeon is initiating today.
Agreed as a shared conclusion, not a lingering disagreement: his existing history already substantively meets the field's working definition of treatment-refractory, and DBS referral is the appropriate next step rather than continued serial medication trials — a genuine consensus reached by all three voices once the one specific documentation gap was named and addressed directly.